m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01726)
Name
N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
Synonyms
CHEMBL198543; N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H14N2O4
InChI
1S/C15H14N2O4/c18-14(17-20)10-16-15(19)11-6-8-13(9-7-11)21-12-4-2-1-3-5-12/h1-9,20H,10H2,(H,16,19)(H,17,18)
InChIKey
NBSITGWGPCATOG-UHFFFAOYSA-N
PubChem CID
44404537
TTD Drug ID
D09SYW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-1 (MMP-1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). [1], [2]
References
Ref 1 METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response. Life Sci. 2021 Aug 1;278:119528. doi: 10.1016/j.lfs.2021.119528. Epub 2021 Apr 21.
Ref 2 Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. doi: 10.1016/s0960-894x(99)00285-1.